Humacyte, Inc. (HUMA) stock
Close on Nov 11, 2026Market cap $164.37MP/E –Yield –
Humacyte, Inc. grew revenue 52.5% to $2.40M over the twelve months to Sep 30, 2026. Free cash flow was -$88.58M. At the latest close the market valued the company at $164.37M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $164.37M
- P/E ratio
- –
- Price to sales
- 68.60
- Price to book
- 9.10
- Dividend yield
- –
- Free cash flow yield
- -53.89%
Fundamentals
- Revenue
- $2.40M
- Net income
- -$94.76M
- EPS, diluted
- -$0.44
- Free cash flow
- -$88.58M
- Book value per share
- $0.07
- Diluted shares
- 278M
Trading
- Next earnings
- Mar 18, 2027 (estimated, before the open)
- Previous close
- $0.59
- Open
- $0.59
- Day's range
- $0.55 – $0.63
- Volume
- 6,778,329
- Average volume (20 days)
- 5,745,258
- Beta (5 years)
- 2.06
- 52-week range
- $0.34 – $1.52
- RSI (14 days)
- 64.9
- Volatility (1 year)
- 114.6%
- Relative volume
- 1.06×
- WACC
- 15.2%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HUMA | S&P 500 | Difference | HUMA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +46.0% | -2.4% | +48.4 pts | ||
| 3 months | -16.7% | -1.2% | −15.5 pts | ||
| Year to date | -38.4% | +12.3% | −50.7 pts | ||
| 1 year | -53.8% | +12.4% | −66.2 pts | ||
| 3 years | -74.8% | +78.8% | −153.6 pts | -36.9% | +21.4% |
| 5 years | -94.0% | +75.2% | −169.1 pts | -43.0% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Humacyte filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Update
- News
About Humacyte
Biological Products, (No Diagnostic Substances)
Humacyte, Inc. is a biotechnology company focused on developing and commercializing bioengineered human acellular vessels and tissue engineering technologies. The company operates in program areas and reportable segments that include vascular trauma, arteriovenous (AV) access for hemodialysis, and peripheral arterial disease (PAD). Its medical technologies are targeted toward patients requiring vascular repair, replacement, or reconstruction across acute trauma care and vascular disease treatments.
Company profile, executives and historyHumacyte stock: common questions
What is Humacyte's stock price?
HUMA closed at $0.59 on Nov 11, 2026, up 0.29% on the day. Over the past 52 weeks it traded between $0.34 and $1.52.
What is Humacyte's market cap?
Humacyte was worth $164.37M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is HUMA's P/E ratio?
Humacyte lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.44), so it has no meaningful P/E ratio.
How much revenue does Humacyte make?
Humacyte reported revenue of $2.40M for the twelve months to Sep 30, 2026, up 52.5% from a year earlier.
Does Humacyte pay a dividend?
No. Humacyte has not paid a cash dividend over the last twelve months.
When does Humacyte report earnings next?
Humacyte is expected to report Q4 FY2026 results on Mar 18, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has HUMA stock performed over the past year?
Including dividends, HUMA returned -53.8% over the past year, against +12.4% for the S&P 500.
How many HUMA shares are sold short?
28M shares were sold short at the latest FINRA report, 10.98% of the float, or 7.2 days of average trading volume.
Who are Humacyte's competitors?
Companies most similar to Humacyte by business, industry and size include PROK, DYAI, PLUR, PRME, OTLK.
See a number that looks wrong?